Katy Mazibuko

All filings by Katy Mazibuko on record concern Swedish Orphan Biovitrum AB (publ). The record holds 14 filings, for trades running from 1 November 2019 to 12 August 2026.

The open-market side counts 3 purchases for €6,491 alongside 3 sales for €52k. Sales outweigh purchases by €45k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 5 share grants. So far in 2026, the count stands at 1 purchase and no sales.

In size, the median ticket on the buying side is €2,222. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 17 August 2026, the filings show an open-market purchase worth €2,237 in Swedish Orphan Biovitrum AB (publ). Filings reach the Finansinspektionen feed a median of 4 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.